Oxonica is One of the World’s Most Suitable Nanotechnology Start-Ups for Corporate Partnership, Study Says
OXFORD, England--(BUSINESS WIRE)--Oxonica (AIM:OXN), a leading international nanotechnology group, has been named one of four nanotechnology startups offering the greatest value for potential corporate partners. In a study released October 17, 2006, Lux Research measured 136 venture-capital backed nanotech companies using a comprehensive, quantitative methodology for determining suitability for partnership. Oxonica received an overall score of 85, tied with two other nanotech leaders and one point behind the overall highest scorer.
“Oxonica has been built with corporate partnership at the forefront of our strategy”
“Oxonica has been built with corporate partnership at the forefront of our strategy,” said Kevin Matthews, CEO of Oxonica plc. “We have been working diligently at forging international partnerships to market our industry-leading products and it is exciting to see our work reflected in this top ranking.”
The corporate partnership rankings were developed by Lux Research, a leading nanotech industry research firm, using an evaluation tool with 20 objective criteria spanning four success factors: 1) scientific pipeline; 2) commercial viability; 3) legal and regulatory position; and 4) operational and financial performance. The methodology also incorporated qualitative criteria such as the strength of the companies’ management teams. The tool was applied to all nanotech start-ups worldwide that were independently operating and backed by institutional venture capital as of September 2006, and which had not gone public prior to 2001 for a total of 136 companies.
About Oxonica plc - www.oxonica.com
Oxonica (AIM:OXN) is one of the leading International nanomaterials groups with products already launched into international markets and is listed in London on the AIM market. It was spun-out from Oxford University in 1999 and currently employs 56 professional staff. Oxonica’s mission is to focus on the development of innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. It owns a portfolio of demand driven products that offer substantial benefits to the target markets of energy, healthcare, materials and security.
The Group currently has four operating divisions: Oxonica Energy, Oxonica Healthcare, Oxonica Materials and Oxonica Security. Oxonica has already launched products into international markets. Lead products include:
Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection technologies which will enable a new generation of ultrasensitive multiplex diagnostic tools for the clinical diagnostic life science and security markets. In addition, the company is developing other UV absorber technologies into polymer systems and coatings, based on similar technologies to that used in Optisol™.